Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
about
Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.The pursuit of oncotargets through understanding defective cell regulationCharacterization of lung cancer by amide proton transfer (APT) imaging: an in-vivo study in an orthotopic mouse modelUDP-glucuronosyltransferase 1A determinates intracellular accumulation and anti-cancer effect of β-lapachone in human colon cancer cellsColocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-Lapachone.Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivoPreclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.Hydroxycamptothecin-loaded Fe3O4 nanoparticles induce human lung cancer cell apoptosis through caspase-8 pathway activation and disrupt tight junctions.SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents.RETRACTED: NAD(P)H:quinone oxidoreductase 1 protects lungs from oxidant-induced emphysema in mice.Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging.Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC.Superparamagnetic iron oxide nanoparticles: amplifying ROS stress to improve anticancer drug efficacy.An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosisEsterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.Molecular-targeted nanotherapies in cancer: enabling treatment specificity.Exploring polymeric micelles for improved delivery of anticancer agents: recent developments in preclinical studies.Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments.Drug delivery and nanodetection in lung cancer.Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.Recent updates in utilizing prodrugs in drug delivery (2013-2015).Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.Preclinical Pharmacokinetic Evaluation of β-Lapachone: Characteristics of Oral Bioavailability and First-Pass Metabolism in Rats.Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species.Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity.Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.Lysosome-oriented, dual-stage pH-responsive polymeric micelles for β-Lapachone delivery.A Tumor-Specific Cascade Amplification Drug Release Nanoparticle for Overcoming Multidrug Resistance in Cancers.Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis.Enhancing Oral Absorption of β-Lapachone: Progress Till Date.PhytoNanotechnology: Enhancing Delivery of Plant Based Anti-cancer Drugs.Encapsulation of nor-β-lapachone into poly(d,l)-lactide--glycolide (PLGA) microcapsules: full characterization, computational details and cytotoxic activity against human cancer cell lines
P2860
Q27346846-BBB35B66-68E3-4BF1-8F46-1B07526ED151Q28395166-75D0FF1E-B914-4EFC-8B35-D130F2D31805Q28534416-875CE920-8D7C-445A-9A38-DB39AE4F58BBQ28543502-9EC19D4E-2398-4E4D-8D79-AF2CCE8EFFF5Q30583249-226697D6-3B8C-4801-8F23-38AF4C65F947Q33767952-6F214D6F-C260-4EB2-A4A8-F23D88F6A183Q34047248-0BFDDC6E-DA96-49F4-B56F-DAB84C256F3AQ34104079-0CD1B0D5-A062-4787-9F02-79CCC751E5A6Q34227677-DBDC959D-3050-4D5B-B16F-DBA8D23B40B0Q34995515-6DA473C0-AE74-43CD-8396-3F6900ABE0D6Q35593948-84D45CC8-984C-42E5-A328-E3BCC6C7986AQ35705835-15A7FCA7-6034-402B-AA54-8F9F16FF14B4Q35856376-C783FABA-8A5B-44C6-BED7-72CBBF6BDCAAQ36316513-8FE9DFCC-5BCF-4C83-B683-2AE20D15DC9EQ36471467-180F7367-F265-4623-B904-C5106FBC6BBCQ36619072-DB9ED58C-9FF0-458B-8F72-0807A5CE4A24Q36695591-0DFA751D-858E-4CD9-8432-D3ABAA3B60D1Q36716649-7CB2B20D-EB6E-44D9-9C1C-81D8CA5871BFQ37440695-D820A1A5-8737-45D2-9317-C970FF23CAC7Q37954497-5DA4FC05-9AA8-4D55-9C62-EF2C1CA7C5BBQ38168377-146D5281-652A-4CD8-838F-8F07364B27C5Q38191981-F976F0D3-FC72-427F-9F4E-AF335BA6CB87Q38247299-EC89B37E-BB6B-4327-8F3C-71BCD82B7C13Q38267035-85799F1F-9871-453B-A4DC-C1DCD19C0B9CQ38603364-931E540D-673B-40CF-A399-0D67E9E27347Q38702949-18B2DDD2-15C5-4F83-A76A-D2BE0492CAB2Q38726394-352409FE-F470-4C1B-9BA7-36C9CCA30883Q38762468-840B1DF6-05EC-4DE0-9455-851CD4F24081Q39004214-17E393AC-8B4E-4705-89D4-22054AFDB961Q39099843-5D4886F8-EE44-470A-9E67-BEFDD7DDAD38Q39617420-F80DDD25-BA33-4B60-B192-58ECC03E6C63Q42409402-535BB096-1B38-45AF-8DE2-41E927C92554Q46086889-07F73DD7-BDB5-421E-9A34-5E7F62E9DF55Q46317390-B2B52BC4-2BB6-4D35-ABB4-CAB2929AD762Q47165034-1B74491D-39D8-4AC0-B308-4841027C6EA6Q49108416-38454001-4AE5-4CA0-BA80-E39C9AC13EF8Q50233354-D366AFC5-C52F-4D4C-B800-3357CC721F34Q57150128-16BCB1E6-2B40-4D82-9E13-94C8DC3D7FB9
P2860
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
@ast
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
@en
type
label
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
@ast
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
@en
prefLabel
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
@ast
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
@en
P2093
P2860
P1433
P1476
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
@en
P2093
Chalermchai Khemtong
Chase W Kessinger
David A Boothman
Erik A Bey
Huabing Chen
Jagadeesh Setti-Guthi
Jinming Gao
Kevin A Carnevale
Su-Geun Yang
William G Bornmann
P2860
P304
P356
10.1158/0008-5472.CAN-09-3995
P407
P50
P577
2010-05-11T00:00:00Z